A
Practice-defining evidence
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Scientific intelligence record
Experience 2.0
GLP-1 receptor agonist
Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) engineered for resistance to DPP-4 degradation and prolonged albumin binding. It selectively activates the GLP-1 receptor. In humans, its pharmacologic effects include glucose-dependent stimulation of insulin secretion, reduced glucagon secretion, delayed gastric emptying, reduced calorie intake, and lower body weight. Clinical effects and approved uses depend on the formulation, indication, population, and regulatory jurisdiction; this archive separates those contexts rather than treating semaglutide as a single undifferentiated claim.
Record status
Traceability partial
Last meaningful update: 9/9/2026
Accountable evidence registry
AI appraisal is complete for all 300 screening records. 297 are ready for one accountable bundle sign-off; 3 focused exceptions remain held instead of sending the full corpus through duplicate human review.
Semaglutide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Complete 2D chemical identity. PubChem does not provide a physical 3D conformer for this large flexible molecule; the viewer is residue-order geometry only.
Sources: NIH PubChem — Semaglutide · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). Semaglutide — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 8, 2026.) https://www.worldpeptidefoundation.org/directory/semaglutide
AMA / Vancouver
World Peptide Foundation. Semaglutide — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 8, 2026. https://www.worldpeptidefoundation.org/directory/semaglutide
Ranked research corpus
300
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
37
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
11
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-17. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
300
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
37
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
11
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Semaglutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled claim-to-source graphThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The current US prescribing information defines approved indications, dosing, contraindications, warnings, adverse reactions, pharmacology, and clinical-study evidence for Wegovy. Label claims are jurisdiction-, formulation-, dose-, and revision-specific.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2016 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
systematic_review_or_meta_analysis
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
official_product_labeling
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
2 represented evidence records
Years represented: 2024, 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2024
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2024
Publishing organizations appearing in records: systematic_review_or_meta_analysis
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 11 domain conclusions and 37 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Semaglutide evidence-governance section.
Inspect the reconciled source pathsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/8/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/8/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 2:43:29 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
STEP UP was a phase 3b randomized, double-blind, placebo- and active-controlled trial comparing semaglutide 7.2 mg, 2.4 mg, and placebo in adults with obesity without diabetes.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied. We conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries. Participants with obesity and knee osteoarthritis were randomized to semaglutide or placebo.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
PIONEER 6 randomized 3,183 high-cardiovascular-risk patients with type 2 diabetes to oral semaglutide or placebo. Major adverse cardiovascular events occurred in 3.8% versus 4.8% (hazard ratio 0.79), establishing noninferiority; gastrointestinal events leading to discontinuation were more common with oral semaglutide.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
SUSTAIN FORTE compared weekly semaglutide 2.0 mg with 1.0 mg in 961 adults with inadequately controlled type 2 diabetes. The 2.0 mg dose achieved modestly greater HbA1c and weight reductions with a broadly similar safety profile.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
FLOW randomized 3,533 patients with type 2 diabetes and chronic kidney disease to weekly semaglutide 1.0 mg or placebo. The primary kidney-disease composite risk was lower with semaglutide, and the trial was stopped early after prespecified interim efficacy criteria were met.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
OASIS 1 randomized 667 adults without type 2 diabetes to once-daily oral semaglutide 50 mg or placebo for 68 weeks. Oral semaglutide produced substantially greater weight reduction, with gastrointestinal adverse events more frequent during treatment.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A phase 3a multicenter double-blind trial evaluated coadministered cagrilintide and semaglutide versus active components and placebo for weight management in adults without diabetes.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
SUSTAIN-6 randomized 3,297 patients with type 2 diabetes to weekly semaglutide or placebo for 104 weeks. The primary cardiovascular outcome occurred in 6.6% versus 8.9% (hazard ratio 0.74). Retinopathy complications were more frequent with semaglutide, while new or worsening nephropathy was less frequent.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In a 72-week, phase 3b randomized open-label trial of 751 adults with obesity without type 2 diabetes, mean body-weight change was −13.7% with semaglutide and −20.2% with tirzepatide. Gastrointestinal adverse events were the most common adverse events in both groups. Interpretation is limited to the studied population, doses, duration, active comparator, and open-label design.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In STEP 2, 1,210 adults with overweight or obesity and type 2 diabetes were randomized to semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo. At 68 weeks, mean body-weight change was −9.6% with 2.4 mg versus −3.4% with placebo; gastrointestinal adverse events were more frequent with semaglutide. Results are specific to the studied population and duration.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This exploratory off-treatment extension followed 327 STEP 1 participants after withdrawal. Participants previously receiving semaglutide regained 11.6 percentage points of lost weight by week 120, and cardiometabolic measures generally moved toward baseline. The extension involved a subset of the parent trial and assessed withdrawal rather than continued randomized treatment.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to semaglutide 2.4 mg or placebo plus lifestyle intervention. At 68 weeks, mean body-weight change was −14.9% with semaglutide versus −2.4% with placebo; gastrointestinal adverse events and discontinuations for gastrointestinal events were more frequent with semaglutide. Results are limited to the studied population and duration.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A random-effects meta-analysis of four randomized trials comprising 3,613 participants with obesity without diabetes found greater weight reduction with subcutaneous semaglutide than placebo and higher risks of gastrointestinal adverse events and treatment discontinuation. Conclusions inherit the designs, populations, durations, and quality of the included trials.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In STEP 3, 611 adults without diabetes received intensive behavioral therapy and an initial low-calorie diet plus semaglutide 2.4 mg or placebo. At week 68, estimated mean weight change was -16.0% versus -5.7%; gastrointestinal events were more frequent with semaglutide.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
After a 20-week semaglutide run-in, 803 adults were randomized to continue semaglutide 2.4 mg or switch to placebo for 48 weeks. Continued treatment led to further weight loss while switching to placebo led to weight regain.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
STEP 5 randomized 304 adults without diabetes to semaglutide 2.4 mg or placebo for 104 weeks. Semaglutide produced substantially greater sustained weight reduction; gastrointestinal disorders were the most frequent adverse events.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
STEP 6 studied 401 adults in East Asia with overweight or obesity, with or without type 2 diabetes. Semaglutide 2.4 mg produced greater weight reduction than placebo at 68 weeks, with gastrointestinal disorders the most frequent adverse events.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
STEP 8 randomized 338 adults without diabetes to weekly semaglutide 2.4 mg, daily liraglutide 3.0 mg, or matched placebo. At 68 weeks, semaglutide produced greater mean weight reduction than liraglutide; gastrointestinal adverse events were common in both active groups.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In STEP TEENS, 201 adolescents with obesity, or overweight plus a weight-related condition, were randomized to semaglutide 2.4 mg or placebo plus lifestyle intervention for 68 weeks. Semaglutide produced a larger BMI reduction; gastrointestinal events were more frequent and cholelithiasis occurred in the semaglutide group.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Major adverse cardiovascular events occurred in 6.5% with semaglutide and 8.0% with placebo (hazard ratio 0.80); treatment discontinuation for adverse events was more frequent with semaglutide.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A small phase 2 double-blind randomized trial evaluated once-weekly semaglutide for alcohol consumption and craving in adults with alcohol use disorder.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A double-blind event-driven superiority trial evaluated oral semaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated baseline based on evidence tier; full-text risk-of-bias review may revise it
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This narrative review describes semaglutide molecular design, albumin-binding protraction, GLP-1 receptor pharmacology, and clinical development. It is useful for background and mechanism context but is not a primary efficacy estimate.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Systematic review and meta-analysis of randomized trials examining long-term efficacy and safety of once-weekly semaglutide for weight loss in adults without diabetes.
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2024
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2024
Publishing organizations appearing in records: peer_reviewed_research